Evidence-Based Reviews

A clinical approach to pharmacotherapy for personality disorders

Current Psychiatry. 2021 April;20(4):26-32 | doi:10.12788/cp.0112

References

1. Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association; 2013.
2. Black DW, Andreasen N. Personality disorders. In: Black DW, Andreasen N. Introductory textbook of psychiatry, 7th edition. American Psychiatric Publishing; 2020:410-423.
3. Black DW, Blum N, Pfohl B, et al. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Pers Disord 2004;18(3):226-239.
4. Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196(1):4-12.
5. Vita A, De Peri L, Sacchetti E. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder – a meta-analysis of randomized controlled and open-label trials. J Clin Psychopharmacol. 2011;31(5):613-624.
6. Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder – current evidence and recent trends. Curr Psychiatry Rep. 2015;17(1):534.
7. Hancock-Johnson E, Griffiths C, Picchioni M. A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs. 2017;31(5):345-356.
8. Black DW, Paris J, Schulz SC. Personality disorders: evidence-based integrated biopsychosocial treatment of borderline personality disorder. In: Muse M, ed. Cognitive behavioral psychopharmacology: the clinical practice of evidence-based biopsychosocial integration. John Wiley & Sons; 2018:137-165.
9. Stoffers-Winterling J, Sorebø OJ, Lieb K. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep. 2020;22(8):37.
10. Lewis G, Appleby L. Personality disorder: the patients psychiatrists dislike. Br J Psychiatry. 1988;153:44-49.
11. Black DW, Pfohl B, Blum N, et al. Attitudes toward borderline personality disorder: a survey of 706 mental health clinicians. CNS Spectr. 2011;16(3):67-74.
12. Langbehn DR, Pfohl BM, Reynolds S, et al. The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interview. J Pers Disord. 1999;13(1):75-89.
13. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality (SIDP-IV). American Psychiatric Press; 1997.
14. First MB, Spitzer RL, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). Part II: multisite test-retest reliability study. J Pers Disord. 1995;9(2):92-104.
15. Bateman A, Gunderson J, Mulder R. Treatment of personality disorders. Lancet. 2015;385(9969):735-743.
16. Zanarini MC, Frankenburg FR, Reich DB, et al. Treatment rates for patients with borderline personality disorder and other personality disorders: a 16-year study. Psychiatr Serv. 2015;66(1):15-20.
17. Black DW, Allen J, McCormick B, et al. Treatment received by persons with BPD participating in a randomized clinical trial of the Systems Training for Emotional Predictability and Problem Solving programme. Person Ment Health. 2011;5(3):159-168.
18. Yang Y, Glenn AL, Raine A. Brain abnormalities in antisocial individuals: implications for the law. Behav Sci Law. 2008;26(1):65-83.
19. Ruocco AC, Amirthavasagam S, Choi-Kain LW, et al. Neural correlates of negative emotionality in BPD: an activation-likelihood-estimation meta-analysis. Biol Psychiatry. 2013;73(2):153-160.
20. Livesley WJ, Jang KL, Jackson DN, et al. Genetic and environmental contributions to dimensions of personality disorder. Am J Psychiatry. 1993;150(12):1826-1831.
21. Slutske WS. The genetics of antisocial behavior. Curr Psychiatry Rep. 2001;3(2):158-162.
22. Ripoll LH, Triebwasser J, Siever LJ. Evidence-based pharmacotherapy for personality disorders. Int J Neuropsychopharmacol. 2011;14(9):1257-1288.
23. National Institute for Health and Care Excellence (NICE). Borderline personality disorder: recognition and management. Clinical guideline [CG78]. Published January 2009. https://www.nice.org.uk/guidance/cg78
24. National Institute for Health and Care Excellence (NICE). Antisocial personality disorder: prevention and management. Clinical guideline [CG77]. Published January 2009. Updated March 27, 2013. https://www.nice.org.uk/guidance/cg77
25. Khalifa N, Duggan C, Stoffers J, et al. Pharmacologic interventions for antisocial personality disorder. Cochrane Database Syst Rep. 2010;(8):CD007667.
26. Stoffers JM, Völlm BA, Rücker G, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;2012(8):CD005652.
27. Black DW. The treatment of antisocial personality disorder. Current Treatment Options in Psychiatry. 2017. https://doi.org/10.1007/s40501-017-0123-z
28. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280(8):708-713.
29. Ansseau M. The obsessive-compulsive personality: diagnostic aspects and treatment possibilities. In: Den Boer JA, Westenberg HGM, eds. Focus on obsessive-compulsive spectrum disorders. Syn-Thesis; 1997:61-73.
30. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64(6):628-634.
31. Black DW, Zanarini MC, Romine A, et al. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171(11):1174-1182.
32. Nickel MK, Muelbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163(5):833-838.
33. Crawford MJ, Sanatinia R, Barrett B, et al; LABILE study team. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018;175(8):756-764.
34. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry. 2004;65(12)1660-1665.
35. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45(2):111-119.
36. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
37. Ratey JJ, Gutheil CM. The measurement of aggressive behavior: reflections on the use of the Overt Aggression Scale and the Modified Overt Aggression Scale. J Neuropsychiatr Clin Neurosci. 1991;3(2):S57-S60.
38. Spielberger CD, Sydeman SJ, Owen AE, et al. Measuring anxiety and anger with the State-Trait Anxiety Inventory (STAI) and the State-Trait Anger Expression Inventory (STAXI). In: Maruish ME, ed. The use of psychological testing for treatment planning and outcomes assessment. Lawrence Erlbaum Associates Publishers; 1999:993-1021.
39. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory II. Psychological Corp; 1996.
40. Watson D, Clark LA. The PANAS-X: Manual for the Positive and Negative Affect Schedule – Expanded Form. The University of Iowa; 1999.
41. Harvey D, Greenberg BR, Serper MR, et al. The affective lability scales: development, reliability, and validity. J Clin Psychol. 1989;45(5):786-793.
42. Zanarini MC, Vujanovic AA, Parachini EA, et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Person Disord. 2003:17(3):233-242.
43. Pfohl B, Blum N, St John D, et al. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a new scale to measure severity and change in borderline personality disorder. J Person Disord. 2009;23(3):281-293.
44. Ahearn EP. The use of visual analog scales in mood disorders: a critical review. J Psychiatr Res. 1997;31(5):569-579.

A clinical approach to pharmacotherapy for personality disorders

References

Bottom Line

Related Resources

Drug Brand Names

Pages

Recommended Reading